Search hospitals > Florida > Clearwater
Clinical Research of West Florida, Inc.
Claim this profileClearwater, Florida 33765
Global Leader in Systemic Lupus Erythematosus
Global Leader in Crohn's Disease
Conducts research for Rheumatoid Arthritis
Conducts research for Lupus
Conducts research for Chronic Obstructive Pulmonary Disease
155 reported clinical trials
5 medical researchers
Summary
Clinical Research of West Florida, Inc. is a medical facility located in Clearwater, Florida. This center is recognized for care of Systemic Lupus Erythematosus, Crohn's Disease, Rheumatoid Arthritis, Lupus, Chronic Obstructive Pulmonary Disease and other specialties. Clinical Research of West Florida, Inc. is involved with conducting 155 clinical trials across 107 conditions. There are 5 research doctors associated with this hospital, such as Robert Levin, MD, Leonard Dunn, Leonard Jay Dunn, and Robert William Levin.Area of expertise
1Systemic Lupus Erythematosus
Global Leaderanti-dsDNA positive
ANA positive
anti-Sm positive
2Crohn's Disease
Global LeaderTop PIs
Robert Levin, MDClinical Research of West Florida, Inc. (Clearwater)4 years of reported clinical research
Studies Systemic Lupus Erythematosus
Studies Rheumatoid Arthritis
21 reported clinical trials
29 drugs studied
Leonard DunnClinical Research of West Florida, Inc. (Clearwater)5 years of reported clinical research
Studies Chronic Obstructive Pulmonary Disease
Studies Frailty
8 reported clinical trials
8 drugs studied
Leonard Jay DunnClinical Research of West Florida, Inc. (Clearwater)4 years of reported clinical research
Studies Type 2 Diabetes
Studies Crohn's Disease
6 reported clinical trials
10 drugs studied
Robert William LevinClinical Research of West Florida, Inc. (Clearwater)3 years of reported clinical research
Studies Nail Conditions
Studies Systemic Lupus Erythematosus
2 reported clinical trials
3 drugs studied
Clinical Trials running at Clinical Research of West Florida, Inc.
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Lupus
Psoriatic Arthritis
Sjogren's Syndrome
Sjögren's Syndrome
Chronic Obstructive Pulmonary Disease
Cardiovascular Disease
Smoking
Type 2 Diabetes
Ianalumab
for Lupus
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Recruiting1 award Phase 31 criteria
Upadacitinib
for Lupus
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Recruiting1 award Phase 310 criteria
Cenerimod
for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Recruiting1 award Phase 32 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Clinical Research of West Florida, Inc.?
Clinical Research of West Florida, Inc. is a medical facility located in Clearwater, Florida. This center is recognized for care of Systemic Lupus Erythematosus, Crohn's Disease, Rheumatoid Arthritis, Lupus, Chronic Obstructive Pulmonary Disease and other specialties. Clinical Research of West Florida, Inc. is involved with conducting 155 clinical trials across 107 conditions. There are 5 research doctors associated with this hospital, such as Robert Levin, MD, Leonard Dunn, Leonard Jay Dunn, and Robert William Levin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.